Can fecal microbiota transplantation cure irritable bowel syndrome?

Halkjær, Sofie Ingdam; Boolsen, Anders Watt; Günther, Stig; Christensen, Alice Højer; Petersen, Andreas Munk

doi:10.3748/wjg.v23.i22.4112

Cited by 52 publications

(41 citation statements)

References 36 publications

(85 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Frozen FMT suspensions were not inferior to fresh suspensions (59). A recent review combined data of case reports and studies treating IBS patients with FMT (60). When compiling all small uncontrolled studies, its authors found an overall improvement of symptoms in 58% of patients treated with FMT.…”

Section: Irritable Bowel Syndromementioning

confidence: 99%

Clinical Application and Potential of Fecal Microbiota Transplantation

et al. 2019

View full text Add to dashboard Cite

Fecal microbiota transplantation (FMT) is a well-established treatment for recurrent Clostridioides difficile infection. FMT has become a more readily available and useful new treatment option as a result of stool banks. The current state of knowledge indicates that dysbiosis of the gut microbiota is implicated in several disorders in addition to C. difficile infection. Randomized controlled studies have shown FMT to be somewhat effective in treating ulcerative colitis, irritable bowel syndrome, and hepatic encephalopathy. In addition, FMT has been beneficial in treating several other conditions, such as the eradication of multidrug-resistant organisms and graft-versus-host disease. We expect that FMT will soon be implemented as a treatment strategy for several new indications, although further studies are needed.

show abstract

Section: Irritable Bowel Syndromementioning

confidence: 99%

Clinical Application and Potential of Fecal Microbiota Transplantation

et al. 2019

View full text Add to dashboard Cite

show abstract

“…2,3 The view that an imbalance in the microbial community (dysbiosis) is an underlying cause of sickness provides a rationale for establishing commensal Koch's postulates for microbiota research 4 and raises hope that administering fecal microbiota transplants (FMTs) to eradicate a microbial imbalance could be developed as a cure. 5,6 The latter approach is successful in treating antibioticassociated colitis, 7 because here the FMT directly targets the underlying defect, namely an antibiotic-mediated disruption of the gut microbiota. 8 However, lasting benefits of FMT remain to be established for diseases associated with dysbiosis developing independently of antibiotic treatment.…”

Section: Introductionmentioning

confidence: 99%

Healthy hosts rule within: ecological forces shaping the gut microbiota

2018

View full text Add to dashboard Cite

A balanced gut microbiota is important for human health, but the mechanisms that maintain homeostasis are incompletely understood. Recent insights suggest the host plays a key role in shaping its gut microbiota to be beneficial. While host control in the small intestine curbs bacterial numbers to avoid competition for simple sugars and amino acids, the host limits oxygen availability in the large intestine to obtain microbial fermentation products from fiber. Epithelial cells are major players in imposing ecological control mechanisms, which involves the release of antimicrobial peptides by small-intestinal Paneth cells and maintenance of luminal anaerobiosis by epithelial hypoxia in the colon. Harnessing these epithelial control mechanisms for therapeutic means could provide a novel lynchpin for strategies to remediate dysbiosis.

show abstract

“…Treatments aimed at altering gut microbiota such as antibiotics, probiotics, and case series of FMT have been described in IBS patients. Published case reports of FMT for treatment of IBS have shown improvement, but there is likely a publication bias, with negative reports not published . Additionally, since IBS is a heterogeneous disorder, the success of microbiota restoration in this population would be difficult to ascertain.…”

Section: Microbiota Replacement For Indications Other Than CDImentioning

confidence: 99%

Microbiota Replacement Therapies: Innovation in Gastrointestinal Care

Khanna

2017

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

There has been an increasing interest in the association between human disease and altered gut microbiota, and therapeutics to modulate microbiota to treat disease. Healthy human gastrointestinal microbiota is highly diverse and rich, and harbors between 500 and 2,000 species. Diseases associated with dysbiotic microbiota include antibiotic‐associated diarrhea, Clostridium difficile infection, multidrug‐resistant organisms, inflammatory bowel disease, obesity, metabolic syndrome, diabetes mellitus, neuropsychiatric diseases, and systemic autoimmune diseases. Microbiota replacement therapies have shown immense promise in treatment of recurrent C. difficile infection and are being studied for other indications. Microbiota replacement therapies for indications other than C. difficile infection should be performed only in research settings. There is an immense need for standardized microbiota replacement therapies for C. difficile infection. Studies are needed to elucidate long‐term safety and adverse events from these therapies.

show abstract

Can fecal microbiota transplantation cure irritable bowel syndrome?

Cited by 52 publications

References 36 publications

Clinical Application and Potential of Fecal Microbiota Transplantation

Clinical Application and Potential of Fecal Microbiota Transplantation

Healthy hosts rule within: ecological forces shaping the gut microbiota

Microbiota Replacement Therapies: Innovation in Gastrointestinal Care

Contact Info

Product

Resources

About